Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antiparasitics

Set Alert for Antiparasitics

Zoetis believes Simparica Trio will enjoy competitor-free year

Zoetis expects its new triple combination antiparasitic to not face any competition for the time being.

Zoetis Antiparasitics

New Animal Pharm special report looks at animal care growth drivers 2020-2030

The quest for animal health innovation has accelerated tremendously over recent years, as leading players develop strategies to offset the maturation of product portfolios.

Antiparasitics Diagnostics

Zoetis launches Simparica Trio on time, as full-year projections lowered

Zoetis expects lower-than-projected annual revenues from Simparica Trio – the firm's new triple combination parasiticide.

Zoetis Antiparasitics

Merck strengthens US pet health assets with $400m deal for Virbac's Sentinel

Merck Animal Health is to gain the US rights to the Sentinel family of combination parasiticides for companion animals.

Merck MSD Animal Health Antiparasitics

Aurora bags generic selamectin approval in the US

Minnesota-based Aurora Pharmaceutical has been given approval in the US for a generic antiparasitic for companion animals. 

Product Approvals Antiparasitics

Zoetis combines preventative care delivery and insurance with Pumpkin launch

Zoetis has become the first major animal health player to launch its own dual pet insurance and preventative care business with the introduction of Pumpkin. 

Zoetis Companion Animals

European authorities look at environmental risk of antiparasitics

The European Medicines Agency (EMA) is taking a closer look at the environmental risk from veterinary parasiticides for companion animals.

EMA Antiparasitics

FDA joins calls for more research on ivermectin viability as COVID-19 treatment

The US FDA has suggested extra testing needs to be done to ascertain the viability of ivermectin as a COVID-19 treatment.

FDA Policy & Regulation

Chanelle secures FDA approval for selamectin-based generic

Ireland's Chanelle has gained US FDA authorization for a generic companion animal topical antiparasitic.

Product Approvals Antiparasitics

Boragen lays out translational pipeline as start-up heads toward series B

Boragen may be a relatively small organization but the start-up's roots are linked to industry leader Zoetis' former parent company Pfizer. The North Carolina-based company talked to Animal Pharm analyst Sian Lazell about its pipeline of antiparasitic, immunological and antiprotozoal programs.

Antiparasitics Companion Animals

Zoetis gets first US authorization for triple combo antiparasitic with Simparica Trio

Zoetis' Simparica Trio has become the first commercial combination isoxazoline for dogs in the US after receiving FDA approval.

United States Antiparasitics

Simparica Trio represents latest instalment of Zoetis' antiparasitic progression

In the video interview below, Nadia Koziar – director of global commercial development at Zoetis – speaks about the evolution of the company's antiparasitic portfolio. Ms Koziar was talking to Animal Pharm editor Joseph Harvey at the recent launch of Simparica Trio.

Antiparasitics Canine
See All
UsernamePublicRestriction

Register